Hexokinase 2 is dispensable for T cell-dependent immunity.
Manan M MehtaSamuel E WeinbergElizabeth M SteinertKrishan ChhibaCarlos Alberto MartinezPeng GaoHarris R PerlmanPaul BryceNissim HayNavdeep S ChandelPublished in: Cancer & metabolism (2018)
HK2 is a highly upregulated enzyme in cancer and in T cells. The requirement for HK2 in various cancer models has been described previously. Our finding that T cells are able to withstand the loss of HK2 indicates that HK2 may be a promising candidate for cancer therapy. Furthermore, we identify several other potential metabolic targets in T-ALL leukemia that could spare T cell function.